title: Lerisetron. FAES.
abstract: Lerisetron is a 5-hydroxytryptamine3 receptor antagonist under development by FAES Farma for the potential treatment of emesis resulting from chemotherapy. Phase I trials of lerisetron were underway in Spain by 1994, and as of June 2000, the compound was in phase II trials in the UK. By the end of 2001, phase II trials had been completed and phase III trials had commenced.
authors: Axovan Ltd, Gewerbestrasse 16, 4123 Ailschwil, Switzerland. richard.huckle@axovan.com
authors: Richard
authors: R
authors: Huckle
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001562:Benzimidazoles / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D010880:Piperidines / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D001562:Benzimidazoles; D015507:Drugs, Investigational; D010880:Piperidines; C115094:lerisetron